Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MF59-Adjuvanted H7N9 Vaccine in Healthy Older Adults
NCT02213354Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2014
- Primary completion
- Jul 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MF59-adjuvanted H7N9 vaccine in Avian Influenza (AI) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Percentage of subjects achieving a serum HAI antibody titer of 1:40 or greater, Percentage of subjects achieving HAI seroconversion and 2 more. Started Oct 2014; status: completed.
02
Drugs
MF59-adjuvanted H7N9 vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT02213354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213354.